Predictive factors of neoadjuvant immune checkpoint blockade in melanoma

Predictive factors of neoadjuvant immune checkpoint blockade in melanoma

This review describes the current body of literature and ongoing clinical trials examining neoadjuvant immune checkpoint inhibitors (ICI) for patients with resectable stage III and IV melanoma. Based on prior success in treating metastatic melanoma and as adjuvant therapy, ICIs are being explored in...

Full description

Bibliographic Details
Main Authors: Melissa Sarver, Michael C. Brown, Kristen E. Rhodin, April K. S. Salama, Georgia M. Beasley
Format: Article
Language:English
Published: Taylor & Francis Group 2022-05-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
melanoma
lymph nodes
immune therapy
neoadjuvant
Online Access:http://dx.doi.org/10.1080/21645515.2021.1943987

Internet

http://dx.doi.org/10.1080/21645515.2021.1943987

Similar Items